1-3 of 3
Michael E. Williams
Close
Sort by
Journal Articles

Dose-finding study of ibrutinib and venetoclax in relapsed or refractory mantle cell lymphoma

Clinical Trials & Observations
Craig A. Portell, Nolan A. Wages, Brad S. Kahl, Lihua E. Budde, Robert W. Chen, Jonathon B. Cohen, Nikole E. Varhegyi, Gina R. Petroni, Michael E. Williams
Journal: Blood Advances
Blood Adv (2022) 6 (5): 1490–1498.
https://doi.org/10.1182/bloodadvances.2021005357
Published: 2022
Includes: Supplemental data
Journal Articles

Extrinsic interactions in the microenvironment in vivo activate an antiapoptotic multidrug-resistant phenotype in CLL

Kallesh D. Jayappa, Vicki L. Gordon, Christopher G. Morris, Briana Wilson, B. Dharmaveer Shetty, Konrad J. Cios, Puja C. Arora, Krista M. Isaac, Shekhar Saha, Timothy P. Bender, Michael E. Williams, Craig A. Portell, Michael J. Weber
Journal: Blood Advances
Blood Adv (2021) 5 (17): 3497–3510.
https://doi.org/10.1182/bloodadvances.2020003944
Published: 2021
Includes: Supplemental data
Journal Articles

Microenvironmental agonists generate de novo phenotypic resistance to combined ibrutinib plus venetoclax in CLL and MCL

Kallesh D. Jayappa, Craig A. Portell, Vicki L. Gordon, Brian J. Capaldo, Stefan Bekiranov, Mark J. Axelrod, L. Kyle Brett, Julia D. Wulfkuhle, Rosa I. Gallagher, Emanuel F. Petricoin, Timothy P. Bender, Michael E. Williams, Michael J. Weber
Journal: Blood Advances
Blood Adv (2017) 1 (14): 933–946.
https://doi.org/10.1182/bloodadvances.2016004176
Published: 2017
Includes: Supplemental data